JAGX
Price
$3.66
Change
-$0.29 (-7.34%)
Updated
Oct 2 closing price
Capitalization
3.13M
47 days until earnings call
Intraday BUY SELL Signals
TLSA
Price
$1.12
Change
-$0.02 (-1.75%)
Updated
Oct 2 closing price
Capitalization
124.78M
Intraday BUY SELL Signals
Interact to see
Advertisement

JAGX vs TLSA

JAGX vs TLSA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
JAGX vs. TLSA commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAGX is a Hold and TLSA is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
JAGX vs TLSA: Fundamental Ratings
JAGX
TLSA
OUTLOOK RATING
1..100
9671
VALUATION
overvalued / fair valued / undervalued
1..100
8
Undervalued
97
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
9856
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAGX's Valuation (8) in the Pharmaceuticals Generic industry is significantly better than the same rating for TLSA (97) in the Biotechnology industry. This means that JAGX’s stock grew significantly faster than TLSA’s over the last 12 months.

JAGX's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as TLSA (100) in the Biotechnology industry. This means that JAGX’s stock grew similarly to TLSA’s over the last 12 months.

TLSA's SMR Rating (99) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that TLSA’s stock grew similarly to JAGX’s over the last 12 months.

TLSA's Price Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for JAGX (98) in the Pharmaceuticals Generic industry. This means that TLSA’s stock grew somewhat faster than JAGX’s over the last 12 months.

TLSA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that TLSA’s stock grew similarly to JAGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAGXTLSA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 16 days ago
80%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 1 day ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (JAGX: $3.95 vs. TLSA: $1.12)
Brand notoriety: JAGX and TLSA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAGX: 33% vs. TLSA: 59%
Market capitalization -- JAGX: $3.13M vs. TLSA: $124.78M
JAGX [@Biotechnology] is valued at $3.13M. TLSA’s [@Biotechnology] market capitalization is $124.78M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAGX’s FA Score shows that 1 FA rating(s) are green while TLSA’s FA Score has 0 green FA rating(s).

  • JAGX’s FA Score: 1 green, 4 red.
  • TLSA’s FA Score: 0 green, 5 red.
According to our system of comparison, JAGX is a better buy in the long-term than TLSA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAGX’s TA Score shows that 4 TA indicator(s) are bullish while TLSA’s TA Score has 7 bullish TA indicator(s).

  • JAGX’s TA Score: 4 bullish, 5 bearish.
  • TLSA’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, TLSA is a better buy in the short-term than JAGX.

Price Growth

JAGX (@Biotechnology) experienced а -44.05% price change this week, while TLSA (@Biotechnology) price change was +10.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

JAGX is expected to report earnings on Nov 18, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
JAGX
Daily Signal:
Gain/Loss:
TLSA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FSEG26.410.29
+1.13%
Fidelity Enhanced Small Cap Growth ETF (FSEG)
CGGE35.100.36
+1.04%
Capital Group Global Equity ETF (CGGE)
QQWZ27.910.27
+0.98%
Pacer Cash COWZ 100-Nasdaq 100 Rotator ETF (QQWZ)
DJD62.57-0.12
-0.19%
Invesco Dow Jones Industrial Average Dividend ETF (DJD)
CPAG98.76-0.24
-0.24%
F/m Compoundr U.S. Aggregate Bond ETF (CPAG)

JAGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, JAGX has been loosely correlated with VKTX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if JAGX jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
-12.22%
VKTX - JAGX
46%
Loosely correlated
-6.41%
FLNA - JAGX
41%
Loosely correlated
+8.92%
TCRT - JAGX
36%
Loosely correlated
+2.59%
MNOV - JAGX
35%
Loosely correlated
-2.69%
RNAZ - JAGX
31%
Poorly correlated
-8.93%
More